Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has shown evidence of cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM). Currently metformin is the guideline-recommended first-line tr...

Source: Cardiovascular Diabetology - November 9, 2020 Category: Cardiology Authors: Tien-Hsing Chen, Yan-Rong Li, Shao-Wei Chen, Yu-Sheng Lin, Chi-Chin Sun, Dong-Yi Chen, Chun-Tai Mao, Michael Wu, Chih-Hsiang Chang, Pao-Hsien Chu and Victor Chien-Chia Wu Tags: Original investigation Source Type: research